Cell line · CVCL_1416
Papers46
1 to 20 of 46
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Cascade-responsive HA-decorated liposome/mesoporous silica nanoplatform co-delivering BMF-219 and 5-FU enhances gastric cancer chemotherapy through Menin- and p53-associated apoptotic signaling. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GAL3ST1-Mediated Histone Tyrosine Sulfation Induced by Cancer-Associated Fibroblasts Promotes Gastric Cancer Metastasis. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| OSMR coordinates a self-perpetuating circuit linking chemoresistance and neutrophil-driven immunosuppression in gastric cancer. | Neoplasia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing the antitumor efficacy using a combination of FGFR4 Inhibitor (H3B-6527) and oxaliplatin in gastric cancer. | Neoplasia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Exosome-derived Menin from cancer-associated fibroblasts promotes gastric cancer progression by activating the HSPA6/JNK/JunD pathway and inducing EMT. | J Transl Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Intratumoral Fusobacterium nucleatum Recruits Tumor-Associated Neutrophils to Promote Gastric Cancer Progression and Immune Evasion. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Proteome-based molecular subtyping and therapeutic target prediction in gastric cancer. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Immune evasion by proteolytic shedding of natural killer group 2, member D ligands in Helicobacter pylori infection. | Front Immunol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Abnormal arginine synthesis confers worse prognosis in patients with middle third gastric cancer. | Cancer Cell Int | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Downregulation of miR‑7 and miR‑153 is involved in Helicobacter pylori CagA induced gastric carcinogenesis and progression. | Int J Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Optogenetic control of YAP can enhance the rate of wound healing. | Cell Mol Biol Lett | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Separation and single-cell analysis for free gastric cancer cells in ascites and peritoneal lavages based on microfluidic chips. | EBioMedicine | 2023 | Its Methods give the RRID and name the line | PubMed | |
| LncRNA LINC01094 Promotes Cells Proliferation and Metastasis through the PTEN/AKT Pathway by Targeting AZGP1 in Gastric Cancer. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer. | EBioMedicine | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
Circular RNA Hsa_circRNA_101996 promotes the development of Gastric Cancer via Upregulating Matrix Metalloproteinases-2/Matrix Metalloproteinases-9 through MicroRNA-143/Ten-eleven translocation-2 Pathway. | J Cancer | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Identification of ARGLU1 as a potential therapeutic target for gastric cancer based on genome-wide functional screening data. | EBioMedicine | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1416/papers